<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04995081</url>
  </required_header>
  <id_info>
    <org_study_id>HBPD04</org_study_id>
    <nct_id>NCT04995081</nct_id>
  </id_info>
  <brief_title>Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate) (PD)</brief_title>
  <acronym>HBPD04</acronym>
  <official_title>&quot;A Randomized, Double-Blind, Single Center, Phase 2, Efficacy and Safety Study of Allogeneic HB-adMSCs vs Placebo for the Treatment of Patients With Parkinson's Disease&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hope Biosciences Stem Cell Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hope Biosciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hope Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, single center, phase 2 study to assess efficacy and&#xD;
      safety of multiple allogeneic HB-adMSCs vs Placebo for the treatment of Parkinson's disease.&#xD;
&#xD;
      The trial includes a screening period of up to 4 weeks, a 32- week treatment period, and a&#xD;
      safety Follow-up period of 20 weeks after the last investigational product administration.&#xD;
&#xD;
      This clinical trial will be open to enroll 60 eligible participants diagnosed with&#xD;
      Parkinson's disease. Patients' recruitment will be conducted by the study team, if eligible&#xD;
      participants are identified based on eligibility criteria, a screening visit will be&#xD;
      scheduled. Informed consent form will be given to the study participants and signed before&#xD;
      any study procedures. Informed consent form will include information about the clinical trial&#xD;
      and some aspects should be considered during this process.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2021</start_date>
  <completion_date type="Anticipated">July 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 20, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A parallel study is a type of clinical study where two groups of treatments, A (allogeneic HB-adMSCs) and B (Placebo), are given so that one group receives only A while another group receives only B.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Study subjects, investigators and study staff will be blinded to the assigned treatment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>1. Changes in the total score MDS-UPDRS Part II.</measure>
    <time_frame>Baseline to Weeks 52.</time_frame>
    <description>Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2. Incidence of treatment-emergent Adverse Event (TEAEs).</measure>
    <time_frame>Baseline to Weeks 52.</time_frame>
    <description>Treatment-emergent Adverse Event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3. Incidence of treatment-emergent Serious Adverse Events (SAEs).</measure>
    <time_frame>Baseline to Weeks 52.</time_frame>
    <description>SSAEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>4. AEs of special interest (serious or non-serious) - thromboembolic events.</measure>
    <time_frame>Baseline to Weeks 52.</time_frame>
    <description>Incidence of thromboembolic events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>5. AEs of special interest (serious or non-serious) - thromboembolism of the extremities</measure>
    <time_frame>Baseline to Weeks 52.</time_frame>
    <description>Incidence and risk of AEs of special interest (serious or non-serious), including peripheral events defined as, thromboembolism of the extremities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6. AEs of special interest (serious or non-serious) - infections</measure>
    <time_frame>Baseline to Weeks 52.</time_frame>
    <description>Incidence and risk of AEs of special interest (serious or non-serious), including infections.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>7. AEs of special interest (serious or non-serious) - hypersensitivities.</measure>
    <time_frame>Baseline to Weeks 52.</time_frame>
    <description>Incidence and risk of AEs of special interest (serious or non-serious), including hypersensitivities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>8. Laboratory value Complete Blood Count (CBC)</measure>
    <time_frame>Baseline to Weeks 52.</time_frame>
    <description>Clinically significant changes in CBC values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>9. Laboratory values Chemistry Metabolic Panel (CMP)</measure>
    <time_frame>Baseline to Weeks 52.</time_frame>
    <description>Number of Participants with changes in Laboratory CMP values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>10. Laboratory values Coagulation Panel; Prothrombin time, Partial Prothrombin time, and INtern</measure>
    <time_frame>Baseline to Weeks 52.</time_frame>
    <description>Number of Participants with changes in Laboratory Coagulation Panel values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>11. Vital signs. - Respiratory Rate (breaths per minute)</measure>
    <time_frame>Baseline to Weeks 52.</time_frame>
    <description>Number of Participants with Clinically significant changes in Respiratory Rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12. Vital signs. - Heart Rate (beats per minute)</measure>
    <time_frame>Baseline to Weeks 52.</time_frame>
    <description>Number of Participants with Clinically significant changes in Heart Rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>13. Vital signs. - Body Temperature (Fahrenheit )</measure>
    <time_frame>Baseline to Weeks 52.</time_frame>
    <description>Number of participants with Clinically significant changes in Heart Rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>14. Vital signs. - Blood Pressure (mmHg)</measure>
    <time_frame>Baseline to Weeks 52.</time_frame>
    <description>Number of Participants with Clinically significant changes in Blood Pressure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>15. Weight in lb.</measure>
    <time_frame>Baseline to Weeks 52.</time_frame>
    <description>Number of Participants with Clinically significant changes in Weight in lb.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>16. Physical examination results. General</measure>
    <time_frame>Baseline to Weeks 52.</time_frame>
    <description>Number of Participants with Clinically significant changes in general physical examination results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>17. Physical examination results. Body Systems.</measure>
    <time_frame>Baseline to Weeks 52.</time_frame>
    <description>Number of Participants with Clinically significant changes in body systems physical examination results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>18. Changes in Movement Disorder Society Unified Parkinson's Disease Rating Scale -UPDRS Part I.</measure>
    <time_frame>Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.</time_frame>
    <description>Changes in MDS-UPDRS Part I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>19. Changes in the total score Movement Disorder Society Unified Parkinson's Disease Rating Scale -UPDRS Part II and Part III.</measure>
    <time_frame>Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.</time_frame>
    <description>Changes in Total score MDS-UPDRS Part II and Part III</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>20. Changes in Movement Disorder Society Unified Parkinson's Disease Rating Scale MDS-UPDRS Part III.</measure>
    <time_frame>Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.</time_frame>
    <description>Changes in MDS-UPDRS Part III</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>21. Changes in Movement Disorder Society Unified Parkinson's Disease Rating Scale MDS-UPDRS Part IV.</measure>
    <time_frame>Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.</time_frame>
    <description>Changes in MDS-UPDRS Part IV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>22. Changes in Short Form 36 Health Survey Questionnaire (SF-36).</measure>
    <time_frame>Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.</time_frame>
    <description>Changes in SF-36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>23. Changes in Parkinson's disease fatigue scale (PFS-16)</measure>
    <time_frame>Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.</time_frame>
    <description>Improvements in Participants PFS-16 scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24. Changes in Parkinson's disease Questionnaire (PDQ-39).</measure>
    <time_frame>Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.</time_frame>
    <description>Improvements in Participants PDQ-39 scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25. Changes in Visual Analog Scale for Pain.</measure>
    <time_frame>Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.</time_frame>
    <description>Changes in Participants VAS Pain Scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>26. Changes in Visual Analog Scale for Muscle spasms.</measure>
    <time_frame>Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.</time_frame>
    <description>Changes in Participants VAS spasms Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>27. Changes in Dosage of medications taken to treat Parkinson's disease.</measure>
    <time_frame>Baseline to Weeks 4, 8, 16, 24, 32, 42 and 52.</time_frame>
    <description>Changes in Participants medications taken</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Allogeneic HB-adMSCs.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Biological/Vaccine: Allogeneic HB-adMSCs&#xD;
Allogeneic HB-adMSCs will be administered intravenously to study participants who qualify.&#xD;
Other Names: Allogeneic Hope Biosciences adipose derived mesenchymal stem cells.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered intravenously to study participants who qualify.&#xD;
Other Names: Sterile Saline Solution 0.9%</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biological/Vaccine: Allogeneic HB-adMSCs</intervention_name>
    <description>HB-adMSCs will be administered intravenously to study participants who qualify.</description>
    <arm_group_label>Allogeneic HB-adMSCs.</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Allogeneic Hope Biosciences adipose derived mesenchymal stem cells.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sterile Saline Solution 0.9%</description>
    <arm_group_label>Allogeneic HB-adMSCs.</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo will be administered intravenously to study participants who qualify.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A study participant will be eligible for inclusion in this study only if all the&#xD;
             following criteria apply:&#xD;
&#xD;
               1. Male and female participants 45 - 80 years of age.&#xD;
&#xD;
               2. At the screening visit, study participants must have an MDS-UPDRS part II score&#xD;
                  between 7 and 28.&#xD;
&#xD;
               3. Study participants must have an MDS-UPDRS part III score between 20 and 57 during&#xD;
                  the screening visit.&#xD;
&#xD;
               4. Carbidopa/Levodopa total dosage must be less than 1200 mg per day for study&#xD;
                  participants.&#xD;
&#xD;
               5. The total Levodopa equivalent dose for study participants must be less than 1400&#xD;
                  mg per day.&#xD;
&#xD;
               6. Study participant must have been diagnosed with early and/or moderate Parkinson's&#xD;
                  disease at least 2 years prior study participation.&#xD;
&#xD;
               7. Study participants should be able to read, understand and to provide written&#xD;
                  consent.&#xD;
&#xD;
               8. Voluntarily signed informed consent obtained before any clinical-trial related&#xD;
                  procedures are performed.&#xD;
&#xD;
               9. Female study participants should not be pregnant or plan to become pregnant&#xD;
                  during study participation and for 6 months after last investigational product&#xD;
                  administration.&#xD;
&#xD;
              10. Male participants if their sexual partners can become pregnant should use a&#xD;
                  method of contraception during study participation and for 6 months after the&#xD;
                  last administration of the investigated product.&#xD;
&#xD;
              11. Study participant is able and willing to comply with the requirements of this&#xD;
                  clinical trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A study participant will not be eligible for inclusion in this clinical trial if any&#xD;
             of the following criteria apply:&#xD;
&#xD;
               1. Pregnancy, lactation. Women of childbearing age who are not pregnant but do not&#xD;
                  take effective contraceptive measures.&#xD;
&#xD;
               2. Study participants with advanced Parkinson's disease described as, severe&#xD;
                  disability, wheelchair bound or bedridden.&#xD;
&#xD;
               3. Study participant has any active malignancy, including evidence of cutaneous&#xD;
                  basal, squamous cell carcinoma or melanoma.&#xD;
&#xD;
               4. Study participant has known alcoholic addiction or dependency or has current&#xD;
                  substance use or abuse.&#xD;
&#xD;
               5. Study participant has 1 or more significant concurrent medical conditions&#xD;
                  (verified by medical records), including the following:&#xD;
&#xD;
                    -  Poorly controlled diabetes mellitus (PCDM) defined as history of deficient&#xD;
                       standard of care treatment and/or pre-prandial glucose &gt;130mg/dl during&#xD;
                       screening visit or post-prandial glucose &gt;200mg/dl.&#xD;
&#xD;
                    -  Medical History of Chronic kidney disease (CKD) diagnosis and/or screening&#xD;
                       results of eGFR &lt; 59mL/min/1.73m2.&#xD;
&#xD;
                    -  Presence of New York Heart Association (NYHA) Class III/IV heart failure&#xD;
                       during screening visit.&#xD;
&#xD;
                    -  Any medical history of myocardial infarction in any of the different types,&#xD;
                       such as ST-elevation myocardial infarction (STEMI) or non-ST-elevated&#xD;
                       myocardial infarction (NSTEMI), coronary spasm, or unstable angina.&#xD;
&#xD;
                    -  Medical history of uncontrolled high blood pressure defined as a deficient&#xD;
                       standard of care treatment and/or blood pressure &gt; 180/120 mm/Hg during&#xD;
                       screening visit.&#xD;
&#xD;
                    -  Medical history of inherited thrombophilias, recent major general surgery,&#xD;
                       (within 12 months before the Screening), lower extremity paralysis due to&#xD;
                       spinal cord injury, fracture of the pelvis, hips or femur, cancer of the&#xD;
                       lung, brain, lymphatic, gynecologic system (ovary or uterus), or&#xD;
                       gastrointestinal tract (like pancreas or stomach).&#xD;
&#xD;
                    -  History of brain surgery for Parkinson's disease.&#xD;
&#xD;
               6. Study participant has received any stem cell treatment within 6 months before&#xD;
                  first dose of investigational product other than stem cells produced by Hope&#xD;
                  Biosciences.&#xD;
&#xD;
               7. Receiving any investigational therapy or any approved therapy for investigational&#xD;
                  use within 1 year prior first dose of the investigational product other than&#xD;
                  COVID-19 vaccines.&#xD;
&#xD;
               8. Study participant has a laboratory abnormality during screening, including the&#xD;
                  following:&#xD;
&#xD;
                    -  White blood cell count &lt; 3000/mm3&#xD;
&#xD;
                    -  Platelet count &lt; 80,000mm3&#xD;
&#xD;
                    -  Absolute neutrophil count &lt; 1500/mm3&#xD;
&#xD;
                    -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 10 upper&#xD;
                       limit of normal (ULN) x 1.5&#xD;
&#xD;
               9. Study participant has any other laboratory abnormality or medical condition&#xD;
                  which, in the opinion of the investigator, poses a safety risk or will prevent&#xD;
                  the subject from completing the study.&#xD;
&#xD;
              10. Study participant is unlikely to complete the study or adhere to the study&#xD;
                  procedures.&#xD;
&#xD;
              11. Study participant with known concurrent acute or chronic viral hepatis B or C or&#xD;
                  human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
              12. Study participant has a previously diagnosed psychiatric condition which in the&#xD;
                  opinion of the investigator may affect self-assessments.&#xD;
&#xD;
              13. Study participant with any systemic infection requiring treatment with&#xD;
                  antibiotics, antivirals, or antifungals within 30 days prior to first dose of the&#xD;
                  investigational product.&#xD;
&#xD;
              14. Male study participants who plan to donate sperm during the study or within 6&#xD;
                  months after the last dose. Female patients who plan to donate eggs or undergo in&#xD;
                  vitro fertilization treatment during the study or within 6 months after the last&#xD;
                  dose.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Djamchid Lotfi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hope Biosciences Stem Cell Research Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherry L Diers, RN</last_name>
    <phone>346-900-0340</phone>
    <phone_ext>101</phone_ext>
    <email>sherry@hopebio.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David T Gonzalez,, RN</last_name>
    <phone>346-900-0340</phone>
    <phone_ext>101</phone_ext>
    <email>david@hopebio.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hope Biosciences Stem Cell Research Foundation</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherry L Diers, RN</last_name>
      <phone>346-900-0340</phone>
      <phone_ext>101</phone_ext>
      <email>sherry@hopebio.org</email>
    </contact>
    <contact_backup>
      <last_name>David T Gonzalez, RN</last_name>
      <phone>346-900-0340</phone>
      <phone_ext>101</phone_ext>
      <email>david@hopebio.org</email>
    </contact_backup>
    <investigator>
      <last_name>Djamchid Lotfi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thanh Cheng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cuenca L, Gil-Martinez AL, Cano-Fernandez L, Sanchez-Rodrigo C, Estrada C, Fernandez-Villalba E, Herrero MT. Parkinson's disease: a short story of 200 years. Histol Histopathol. 2019 Jun;34(6):573-591. doi: 10.14670/HH-18-073. Epub 2018 Dec 12. Review.</citation>
    <PMID>30540129</PMID>
  </reference>
  <reference>
    <citation>Goetz CG. The history of Parkinson's disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med. 2011 Sep;1(1):a008862. doi: 10.1101/cshperspect.a008862.</citation>
    <PMID>22229124</PMID>
  </reference>
  <reference>
    <citation>Stoker TB, Greenland JC, editors. Parkinson's Disease: Pathogenesis and Clinical Aspects [Internet]. Brisbane (AU): Codon Publications; 2018 Dec 21. Available from http://www.ncbi.nlm.nih.gov/books/NBK536721/</citation>
    <PMID>30702835</PMID>
  </reference>
  <reference>
    <citation>Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015 Aug 29;386(9996):896-912. doi: 10.1016/S0140-6736(14)61393-3. Epub 2015 Apr 19. Review.</citation>
    <PMID>25904081</PMID>
  </reference>
  <reference>
    <citation>Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020 Feb 11;323(6):548-560. doi: 10.1001/jama.2019.22360. Review.</citation>
    <PMID>32044947</PMID>
  </reference>
  <reference>
    <citation>Tambasco N, Romoli M, Calabresi P. Levodopa in Parkinson's Disease: Current Status and Future Developments. Curr Neuropharmacol. 2018;16(8):1239-1252. doi: 10.2174/1570159X15666170510143821. Review.</citation>
    <PMID>28494719</PMID>
  </reference>
  <reference>
    <citation>Marsden CD. Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol. 1994;17 Suppl 2:S32-44. Review.</citation>
    <PMID>9358193</PMID>
  </reference>
  <reference>
    <citation>Coppin L, Sokal E, Stéphenne X. Thrombogenic Risk Induced by Intravascular Mesenchymal Stem Cell Therapy: Current Status and Future Perspectives. Cells. 2019 Sep 27;8(10). pii: E1160. doi: 10.3390/cells8101160. Review.</citation>
    <PMID>31569696</PMID>
  </reference>
  <reference>
    <citation>Tatsumi K, Ohashi K, Matsubara Y, Kohori A, Ohno T, Kakidachi H, Horii A, Kanegae K, Utoh R, Iwata T, Okano T. Tissue factor triggers procoagulation in transplanted mesenchymal stem cells leading to thromboembolism. Biochem Biophys Res Commun. 2013 Feb 8;431(2):203-9. doi: 10.1016/j.bbrc.2012.12.134. Epub 2013 Jan 9.</citation>
    <PMID>23313481</PMID>
  </reference>
  <reference>
    <citation>Musiał-Wysocka A, Kot M, Majka M. The Pros and Cons of Mesenchymal Stem Cell-Based Therapies. Cell Transplant. 2019 Jul;28(7):801-812. doi: 10.1177/0963689719837897. Epub 2019 Apr 24. Review.</citation>
    <PMID>31018669</PMID>
  </reference>
  <reference>
    <citation>Garretti F, Agalliu D, Lindestam Arlehamn CS, Sette A, Sulzer D. Autoimmunity in Parkinson's Disease: The Role of α-Synuclein-Specific T Cells. Front Immunol. 2019 Feb 25;10:303. doi: 10.3389/fimmu.2019.00303. eCollection 2019. Review.</citation>
    <PMID>30858851</PMID>
  </reference>
  <reference>
    <citation>Meirelles Lda S, Fontes AM, Covas DT, Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 2009 Oct-Dec;20(5-6):419-27. doi: 10.1016/j.cytogfr.2009.10.002. Epub 2009 Nov 18. Review.</citation>
    <PMID>19926330</PMID>
  </reference>
  <reference>
    <citation>Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005 Feb 1;172(3):367-79. Review.</citation>
    <PMID>15684121</PMID>
  </reference>
  <reference>
    <citation>Tan EK, Chao YX, West A, Chan LL, Poewe W, Jankovic J. Parkinson disease and the immune system - associations, mechanisms and therapeutics. Nat Rev Neurol. 2020 Jun;16(6):303-318. doi: 10.1038/s41582-020-0344-4. Epub 2020 Apr 24. Review.</citation>
    <PMID>32332985</PMID>
  </reference>
  <reference>
    <citation>Dimarino AM, Caplan AI, Bonfield TL. Mesenchymal stem cells in tissue repair. Front Immunol. 2013 Sep 4;4:201. doi: 10.3389/fimmu.2013.00201. Review.</citation>
    <PMID>24027567</PMID>
  </reference>
  <reference>
    <citation>Ra JC, Shin IS, Kim SH, Kang SK, Kang BC, Lee HY, Kim YJ, Jo JY, Yoon EJ, Choi HJ, Kwon E. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev. 2011 Aug;20(8):1297-308. doi: 10.1089/scd.2010.0466. Epub 2011 Mar 17.</citation>
    <PMID>21303266</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

